Ketoprofen prices continued to rise during May 2026 across the global market, extending the bullish momentum observed in April due to strong export demand, elevated upstream costs, and tight spot supply. Overseas pharmaceutical buyers, particularly from Europe, India, and Brazil, maintained active procurement ahead of seasonal demand and mid-year production schedules, while Chinese exporters prioritized higher-margin contracts. At the same time, firm prices for aromatic intermediates, environmental compliance inspections, intermittent plant disruptions, and ongoing port congestion in eastern China restricted market availability and supported higher offers. Domestic Chinese demand remained moderate, but robust export activity kept overall market sentiment positive. Looking ahead, the Ketoprofen market is expected to remain firm through June with a mild upward bias, although price increases may moderate as buyers complete inventory replenishment. Continued supply-side constraints, stable feedstock costs, and steady pharmaceutical demand are likely to support the market in the coming months, while logistics improvements or easing supply pressure could cap sharper gains.
The global Ketoprofen market maintained its upward trajectory throughout May 2026, as Chinese exporters continued to benefit from strong overseas pharmaceutical demand, elevated upstream production costs, and tightening spot availability. Following the bullish momentum observed in April, the Chinese Ketoprofen USP FOB Shanghai market witnessed further gains during May, with suppliers retaining firm pricing power amid constrained inventories and sustained procurement activity from regulated export destinations.
Market participants reported that Ketoprofen export-oriented manufacturers in China remained focused on fulfilling high-margin overseas contracts, particularly from Europe, India, and Latin America, where seasonal pharmaceutical demand and inventory replenishment programs for Ketoprofen continued to support active buying interest. Buyers in regulated markets accelerated procurement to secure material ahead of summer production cycles and to avoid potential delays linked to logistics bottlenecks and ongoing compliance inspections across parts of China’s chemical manufacturing sector.
Ketoprofen demand from India remained especially robust during May as pharmaceutical formulators increased purchases of non-steroidal anti-inflammatory drug (NSAID) ingredients ahead of the monsoon and winter demand cycles. Importers across the other nations also maintained healthy Ketoprofen procurement volumes to support retail and hospital supply chains. Meanwhile, European buyers, particularly, continued to secure additional cargoes amid stricter regulatory compliance requirements and concerns over limited near-term spot Ketoprofen availability.
Within China, Ketoprofen domestic consumption remained comparatively moderate and largely limited to baseline restocking from private healthcare channels, as public-sector procurement activity remained subdued. However, the export market more than compensated for the weaker domestic pull, allowing Ketoprofen suppliers to maintain elevated offer levels throughout the month.
On the supply side, upstream cost pressures remained a key driver of market sentiment. Prices of aromatic intermediates, including benzoyl chloride and brominated derivatives used in Ketoprofen synthesis, stayed firm during May due to stable-to-higher benzene and chlorine feedstock values. Industry sources indicated that supplier Ketoprofen inventories at coastal warehouses remained below seasonal norms for most of the month, while forward coverage stayed limited as exporters prioritized contracted shipments over low-priced spot sales.
Logistics conditions also continued to influence the market. Congestion at key eastern Chinese ports, including Ningbo and Shanghai, extended shipment lead times and increased freight scheduling uncertainty, encouraging overseas buyers to place orders earlier than usual. This contributed to a sustained seller-favorable environment across the Asian export market. As a result of these combined factors, Ketoprofen USP FOB Shanghai prices recorded another monthly increase in May, extending the bullish trend established in April. Market sentiment remained cautiously optimistic by month-end, with participants expecting tight Ketoprofen availability and firm export inquiries to persist into the early summer period.
Looking ahead, market analysts anticipate that Ketoprofen prices may continue to witness a mild upward bias through June 2026, supported by stable export demand from regulated pharmaceutical markets and ongoing Ketoprofen procurement ahead of mid-year manufacturing schedules. However, the pace of increase is expected to moderate compared to April and May as some buyers complete Ketoprofen inventory replenishment programs.
